Sugi Predict

Sugi Predict / Compounds / SCHEMBL195996

SCHEMBL195996

SCHEMBL195996

CC(c1c[nH]c2ccccc12)[C@H](N)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR84 Q9NQS5 3/20 0.53
▸ FFAR1 O14842 2/20 0.53
▸ HTR2A P28223 2/20 0.53
▸ HTR2C P28335 2/20 0.53
▸ HTR2B P41595 2/20 0.53
▸ KMT2A Q03164 5/20 0.51
▸ MEN1 O00255 4/20 0.51
▸ MAPT P10636 3/20 0.51
▸ KDM4E B2RXH2 2/20 0.51
▸ APAF1 O14727 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ RECQL P46063 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ MPO P05164 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ BLM P54132 1/20 0.51
▸ PMP22 Q01453 1/20 0.51
▸ HIF1A Q16665 1/20 0.51
▸ PKM P14618 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31646404 1.00 GPR84 (0.53) GPR84FFAR1HTR2AHTR2CHTR2B
SCHEMBL31646035 1.00 GPR84 (0.53) GPR84FFAR1HTR2AHTR2CHTR2B
SCHEMBL31000529 1.00 GPR84 (0.53) GPR84FFAR1HTR2AHTR2CHTR2B
SCHEMBL6588456 1.00 GPR84 (0.53) GPR84FFAR1HTR2AHTR2CHTR2B
SCHEMBL18135252 1.00 GPR84 (0.53) GPR84FFAR1HTR2AHTR2CHTR2B
SCHEMBL31646630 1.00 GPR84 (0.53) GPR84FFAR1HTR2AHTR2CHTR2B
SCHEMBL195995 1.00 GPR84 (0.53) GPR84FFAR1HTR2AHTR2CHTR2B
SCHEMBL31646396 1.00 GPR84 (0.53) GPR84FFAR1HTR2AHTR2CHTR2B
SCHEMBL5913085 1.00 GPR84 (0.53) GPR84FFAR1HTR2AHTR2CHTR2B
SCHEMBL5913301 1.00 GPR84 (0.53) GPR84FFAR1HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11879143-B2 Engineered beta-subunit of tryptophan synthase for production of non-canonical amino acids CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2024-01-23 — — US claimed
US-20160298152-A1 ENGINEERED BETA-SUBUNIT OF TRYPTOPHAN SYNTHASE FOR PRODUCTION OF NON-CANONICAL AMINO ACIDS THE CALIFORNIA INSTITUTE OF TECHNOLOGY 2016-10-13 — — US claimed
CN-118834265-A Polypeptide with complement inhibition activity, fusion protein and medical application thereof 北京拓界生物医药科技有限公司 2024-10-25 — — CN disclosed
US-20240218406-A1 ENGINEERED BETA-SUBUNIT OF TRYPTOPHAN SYNTHASE FOR PRODUCTION OF NON-CANONICAL AMINO ACIDS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2024-07-04 — — US disclosed
US-12024731-B2 Methods and enzyme catalysts for the synthesis of non-canonical amino acids CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2024-07-02 — — US disclosed
CN-118255830-A S1PR2 modulators and uses thereof 北京昌平实验室 2024-06-28 — — CN disclosed
US-20240115655-A1 DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS SIXTH STREET LENDING PARTNERS 2024-04-11 — — US disclosed
EP-4349363-A2 DOSING REGIMENS Apellis Pharmaceuticals, Inc. (US) 2024-04-10 — — EP disclosed
US-20240076317-A1 CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF SIXTH STREET LENDING PARTNERS 2024-03-07 — — US disclosed
US-11903994-B2 Dosing regimens APELLIS PHARMACEUTICALS, INC. (US) 2024-02-20 — — US disclosed
CN-117503905-A dosing regimen 阿佩利斯制药有限公司 2024-02-06 — — CN disclosed
EP-0719274-A1 METHOD FOR DOSING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 1996-07-03 — — EP disclosed
EP-0719273-A1 NUCLEOTIDE ANALOGS GILEAD SCIENCES, INC. (US) 1996-07-03 — — EP disclosed
US-5525611-A ANTITUMOR AGENT, BACTERICIDES, VIRICIDES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 1996-06-11 — — US disclosed
EP-0701557-A1 LAVENDAMYCIN ANALOGS, THEIR USE AND PREPARATION BEHFOROUZ, Mohammad (US) 1996-03-20 — — EP disclosed
WO-1995007920-A1 NUCLEOTIDE ANALOGS GILEAD SCIENCES, INC. (US) 1995-03-23 — — WO disclosed
WO-1995007919-A1 METHOD FOR DOSING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 1995-03-23 — — WO disclosed
WO-1994029308-A1 LAVENDAMYCIN ANALOGS, THEIR USE AND PREPARATION BEHFOROUZ MOHAMMAD (US) 1994-12-22 — — WO disclosed
US-5278191-A Nervous system disorders G. D. SEARLE & CO. (US) 1994-01-11 — — US disclosed
US-5141960-A Central nervous system disorders G. D. SEARLE & CO. (US) 1992-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12024731-B2 Methods and enzyme catalysts for the synthesis of non-canonical amino acids AANAT, AADAT, TPH1 GPR84 3894/4885FFAR1 3292/4885HTR2A 91/4885
US-11903994-B2 Dosing regimens C3AR1, C1QBP, C9 GPR84 1646/4885FFAR1 4296/4885HTR2A 1771/4885
US-20240076317-A1 CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF C3AR1, C5AR1, SERPINC1 GPR84 1323/4885FFAR1 3824/4885HTR2A 2560/4885
US-20240115655-A1 DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS C1QBP, C3AR1, C9 GPR84 2055/4885FFAR1 4331/4885HTR2A 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.